ACRO Biomedical Return On Equity vs. Current Valuation

ACBM Stock  USD 0  0.00  0.00%   
Taking into consideration ACRO Biomedical's profitability measurements, ACRO Biomedical Co may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess ACRO Biomedical's ability to earn profits and add value for shareholders.
For ACRO Biomedical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ACRO Biomedical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ACRO Biomedical Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ACRO Biomedical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ACRO Biomedical Co over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between ACRO Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if ACRO Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACRO Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ACRO Biomedical Current Valuation vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ACRO Biomedical's current stock value. Our valuation model uses many indicators to compare ACRO Biomedical value to that of its competitors to determine the firm's financial worth.
ACRO Biomedical Co is number one stock in return on equity category among its peers. It also is the top company in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ACRO Biomedical's earnings, one of the primary drivers of an investment's value.

ACRO Current Valuation vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

ACRO Biomedical

Return On Equity

 = 

Net Income

Total Equity

 = 
-29.78
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

ACRO Biomedical

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
240.18 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

ACRO Current Valuation vs Competition

ACRO Biomedical Co is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is presently estimated at about 367.21 Million. ACRO Biomedical totals roughly 240.18 Million in current valuation claiming about 65% of stocks in Biotechnology industry.

ACRO Biomedical Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ACRO Biomedical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ACRO Biomedical will eventually generate negative long term returns. The profitability progress is the general direction of ACRO Biomedical's change in net profit over the period of time. It can combine multiple indicators of ACRO Biomedical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products. Acro Biomedical Co., Ltd. was incorporated in 2014 and is based in Fishers, Indiana. Acro Biomedical operates under Biotechnology classification in the United States and is traded on OTC Exchange.

ACRO Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ACRO Biomedical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ACRO Biomedical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ACRO Biomedical's important profitability drivers and their relationship over time.

Use ACRO Biomedical in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ACRO Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ACRO Biomedical will appreciate offsetting losses from the drop in the long position's value.

ACRO Biomedical Pair Trading

ACRO Biomedical Co Pair Trading Analysis

The ability to find closely correlated positions to ACRO Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ACRO Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ACRO Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ACRO Biomedical Co to buy it.
The correlation of ACRO Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ACRO Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ACRO Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ACRO Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ACRO Biomedical position

In addition to having ACRO Biomedical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Restaraunts Hotels Motels Thematic Idea Now

Restaraunts Hotels Motels
Restaraunts Hotels Motels Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Restaraunts Hotels Motels theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaraunts Hotels Motels Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in ACRO Pink Sheet

To fully project ACRO Biomedical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ACRO Biomedical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ACRO Biomedical's income statement, its balance sheet, and the statement of cash flows.
Potential ACRO Biomedical investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although ACRO Biomedical investors may work on each financial statement separately, they are all related. The changes in ACRO Biomedical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ACRO Biomedical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.